Company Filing History:
Years Active: 2017
Title: Inventor Spotlight: Kotiganahalli Narayanagowda Ganeshaiah
Introduction
Kotiganahalli Narayanagowda Ganeshaiah is a prominent inventor based in Bengaluru, India. He has made significant contributions to the field of medicinal chemistry, particularly through his innovative research on cancer treatment and inflammatory disorders. His pioneering efforts have culminated in the development of a unique pharmaceutical compound that holds promise for the medical community.
Latest Patents
Ganeshaiah holds a patent for his invention titled "Chromone alkaloid dysoline for the treatment of cancer and inflammatory disorders." This patent focuses on a novel chromone alkaloid, specifically the compound 5,7-dihydroxy-6-(3-hydroxy-1-methylpiperidin-4-yl)-2-methyl-4H-chromen-4-one. This compound has been identified as a potential inhibitor of cell growth and proliferation, along with its ability to inhibit the production of pro-inflammatory cytokines. The formulations derived from this compound are designed for the treatment of cancer and various inflammatory conditions.
Career Highlights
Currently, Kotiganahalli Narayanagowda Ganeshaiah is affiliated with the Council of Scientific & Industrial Research, where he conducts advanced research in medicinal chemistry and drug development. His work has been instrumental in discovering new therapeutic agents that can provide effective treatments for serious medical conditions.
Collaborations
Throughout his career, Ganeshaiah has collaborated with several notable researchers, including Ram Asrey Vishwakarma and Shreyans Kumar Jain. These partnerships have been vital in advancing his research and expanding the possibilities of his discoveries in the pharmaceutical field.
Conclusion
In conclusion, Kotiganahalli Narayanagowda Ganeshaiah stands out as an influential inventor in the field of medicinal chemistry. His significant patent on chromone alkaloid dysoline underscores his commitment to addressing critical health issues, particularly in cancer and inflammatory disorders. As he continues to work with dedicated colleagues at the Council of Scientific & Industrial Research, the potential for further innovative breakthroughs in treatment options remains high.